Trimarchi becomes president, COO of BridgeBio

BridgeBio Pharma Inc. (NASDAQ:BBIO) named Thomas Trimarchi to the newly created position of president and COO. Trimarchi joined the gene therapy company in 2018 and most recently served as chief product officer.

In August, Lance Baldo will become CEO and Thomas Biancardi CFO of  Beacon Therapeutics Holdings Ltd. Baldo will succeed CEO David Fellows and joins from Freenome Inc. where he was CMO. Biancardi, who replaces Andrew Prosser, was SVP, finance and business planning at Nutrinia Ltd. until 2018, after which he served as consultant CFO to various biopharmas. Fellows will become Beacon’s non-executive chairman. Beacon closed a $170 million series B round this month. ...